LifeBond is developing a series of next-generation biosurgical products which incorporate a proprietary adhesive platform that mimics the biochemical cross-linking cascade of late stage blood coagulation. The adhesive formulation forms a network similar to the fibrin network of blood clots but has demonstrated adhesive strength even greater than that of blood-derived fibrin sealants. LifeBondís technology functions through the rapid and biocompatible in situ cross-linking of structural proteins. As they cross-link, proteins in the physiological environment undergo a process of gelation to form an adhesive hydrogel matrix. The properties of the cross-linking reaction and the hydrogel matrix can be controlled to fit a variety of applications.
Fig: Schematic of the cross-linking that occurs in natural blood clotting and in the curing of fibrin sealants as compared with the cross-linking that occurs in the curing of LifeBondís adhesive formulation (McDermott, et al. Biomacromolecules 2004, 5, 1270-1279)
LifeBond has an extensive portfolio of pending patents related to its core technology. The companyís intellectual property (IP) can be classified into several distinct categories: